Distrofia muscular de Duchenne. Abordaje respiratorio y cuidados paliativos como estrategia de cuidados humanizados

Distrofia Muscular de Duchenne: Abordaje Respiratorio y Cuidados Paliativos como Estrategia de Cuidados Humanizados 68 41. Giménez GC, Müller-Thies M, Prado FJ, Bach JR. Proposed Decannulation Criteria for COVID-19 Patients. Am J Phys Med Rehabil. 2021 Aug 1;100(8):730- 732. doi: 10.1097/ PHM.0000000000001788. 42. World Health Organization/WHO. Datos y cifras. [Internet]. [Consultado: 02/07/2022]. Disponible en: https://www.who.int/es/news-room/fact-sheets/ detail/palliative-care 43. Himelstein BP, Hilden JM, Boldt AM, Weissman D. Pediatric Palliative Care. NEJM [Internet]. 2004 [Consultado: 26/01/2020];350(17):1752–62. Disponible en: https:// www.nejm.org/doi/full/10.1056/NEJMra030334 44. Saad, F. A., Saad, J. F., Siciliano, G.,Merlini, L., &Angelini, C. (2024). DuchenneMuscular Dystrophy Gene Therapy. Current gene therapy, 24(1), 17–28. ht- tps://doi.org/10.2174/15 66523223666221118160932 45. Veerapandiyan, A., & Rao, V. K. (2022). Palliative care in Duchenne muscular dystro- phy: Goals of care discussions and beyond. Muscle & nerve, 65(6), 627–629. https://doi. org/10.1002/mus.27544 46. Rosero, S., Weinstein, J., Seabury, J., Varma, A., Dilek, N., Zizzi, C., Coffey, M., Greco, B., Heatwole, J., Alexandrou, D., Guntrum, D., Ciafaloni, E., & Heatwole, C. (2024). Patient- and caregiver-reported impact of symptoms in Duchenne muscular dystrophy. Muscle & nerve, 70(1), 120–129. https://doi.org/10.1002/ mus.28102 47. KimA, ParkM, ShinHI. Pain characteristics among individualswithDuchennemuscular dystrophy according to their clinical stage. BMC musculoskeletal disorders, 2022 23(1), 536. https://doi.org/10.1186/s12891-022-05504-5 48. Bach JR, Tran J, Durante S. Cost and physician effort analysis of invasive vs noninvasive respiratory management of Duchenne muscular dystrophy. Am J Phys Med Rehabil 2015;94:474–482.SYSTEMATIC REVIEWSystematic Review 119.